Artificial discs are experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement. Many motion preservation companies are reaching critical regulatory milestones that will likely require a step-up in funding to conduct the large scale clinical studies needed to gain PMA approval. Today, companies in this sector are faced with the troubling task of either scaling back R&D programs to conserve cash or raising additional capital to take the next steps. This article first appeared in the June 2008 issue of In Vivo.
by Sharon O’Reilly
With artificial discs experiencing a cooling trend due to an expected reduction in reimbursement for both cervical and lumbar disc...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
